OncoMatch/Clinical Trials/NCT07386158

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Is NCT07386158 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pucotenlimab combination with Vorolanib for vorolanib.

Phase 2RecruitingSun Yat-sen UniversityNCT07386158Data as of May 2026

Treatment: Pucotenlimab combination with Vorolanib — Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Disease stage

Required: Stage T1BN0M0, T2N0M0

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications

Received Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications within 14 days prior to the first use of the investigational drug

Cannot have received: systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion)

Exception: except for local use to control pleural effusion

Perform systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion)

Lab requirements

Blood counts

ANC ≥ 1.5 × 10^9/L (1500/mm3); Platelet count (PLT) ≥ 100 × 10^9/L (100000/mm3); Hemoglobin (HB) ≥ 90 g/L

Kidney function

Preoperative assessment of healthy kidney GFR<60 ml/min through renal dynamic imaging

Liver function

Serum total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; For subjects with liver metastasis, AST and ALT ≤ 5 × ULN; Serum albumin (ALB) ≥ 28g/L

Good organ function, laboratory test results during the screening period meet the following criteria: Hematology... Liver... Coagulation function: INR and APTT ≤ 1.5 × ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify